Profusa, Inc.
Profusa, Inc. is a pioneering digital health company based in the San Francisco Bay Area, dedicated to making the body’s chemistry easily accessible to improve health and wellness. Profusa develops tissue-integrating biosensors for continuous, real-time monitoring of body chemistries, empowering individuals and clinicians with actionable, medical-grade data to transform personal health management and disease prevention. Their unique bioengineering approach overcomes the foreign body response, enabling long-term, in-body monitoring through tiny, flexible biosensors that become one with the body. Profusa’s technology platform supports both consumer and medical applications, with a vision to revolutionize personalized medicine and digital health. The company is supported by significant grant funding from agencies such as DARPA and NIH, and collaborates with leading academic, hospital, and industry partners worldwide.
Patents
Optical filter device, system, and methods for improved optical rejection of high angle of incidence (AOI) light
2025-01-21 • US-12204125-B2
View DetailsWhat We Do
A CE Marked, tissue-integrated biosensor system for continuous, real-time monitoring of tissue oxygen. Designed for use in the clinical management of peripheral artery disease (PAD), chronic wounds, and reconstructive surgery. The platform includes an injectable hydrogel sensor, optical reader, and software for data transmission to smart devices. In the U.S., it is an Investigational Device limited by federal law to investigational use.
Next-generation wireless version of the Lumee Oxygen Platform, CE Marked for use in the European Union. Enables telehealth and remote patient monitoring by providing continuous, real-time tissue oxygen data.
Implantable biosensors capable of simultaneous, continuous monitoring of multiple body chemistries (e.g., oxygen, glucose, lactate, urea, ions). Supported by DARPA and NIH grants, these sensors are designed for long-term integration with body tissue and wireless data transmission.
A flexible, bandage-like reader worn on the skin for continuous wireless monitoring of tissue oxygen in patients with PAD. Developed with support from a $1.5M NIH grant.
Application Area
Show More (3)Battlefield Resuscitation
Psychological and Cognitive Health and Performance
Diagnostics
FDA Regulated Medical Devices
Key People
News & Updates
Profusa received the prestigious Edison Silver Award for its tissue-integrating biosensors enabling long-term continuous monitoring of body chemistry.
Awarded for real-time body chemistry monitoring and innovation in the biochemical sensors market.
Article discusses the promise of Profusa’s microsensing technology for monitoring microvascular perfusion and oxygen supply in tissue, especially for patients with chronic limb-threatening ischemia.
Describes Profusa’s tissue-integrated biosensors that overcome the foreign body response and stream data to mobile devices for personal and medical use.
IEEE Spectrum article on Profusa’s injectable biosensors as the next generation of body sensing technology beyond wearables.
Healthline article on Profusa’s Lumee biosensor, a universal sensor for continuous monitoring of body chemistry stats including glucose and oxygen.
Mail On Sunday article on Profusa’s biosensor implant for diabetic patients, enabling continuous blood chemistry monitoring without finger pricks.
Forbes article on Profusa’s Lumee sensor for long-term continuous monitoring of body chemistry.
Sensor100.com article on Profusa’s injectable sensor for continuous tissue oxygen monitoring, highlighting its biocompatibility and long-term use.
MedGadget article on Profusa’s injectable sensor for continuous oxygen monitoring in tissue, emphasizing its soft hydrogel scaffold and biocompatibility.
Explores the impact of real-time, continuous biochemical monitoring on health risk management, disease prevention, and the future of personalized medicine, highlighting Profusa’s technology.
DARPA-backed study leverages Profusa’s Lumee® Oxygen Platform as part of a larger effort to speed detection and predict disease outbreaks.
New insights from the OMNIA study suggest continuous tissue oxygen monitoring may improve outcomes for patients undergoing endovascular revascularization.
Next-generation wireless device may enable telehealth and remote patient monitoring.
Awarded 2018 Entrepreneurial Company of the Year for real-time body chemistry monitoring.
Profusa Software and Systems Lead, Kevin Zhao, selected as a DARPA Riser to present on military applications of Profusa’s wireless sensing system.
Financing will accelerate commercialization of Lumee™ Oxygen Platform and pioneering glucose biosensors.
Collaboration to develop a flexible-patch reader for continuous monitoring of tissue oxygen.
Funding supports development and commercialization of internal biosensor technology.
Received the 2016 Edison Silver Award in Health and Wellness – Wearable and Sensors category for innovative design and technology.
First clinical application aimed at oxygen monitoring of compromised tissues in PAD.
NIH SBIR grant supports studies of Lumee™ tissue-integrated biosensors for continuous monitoring of oxygen in PAD patients.
Profusa was selected to showcase its 'wear-and-forget' Lumee™ biosensor technology at the Pioneers Festival in Vienna, Austria, highlighting the potential of continuous, real-time body chemistry monitoring.
Profusa’s CEO Ben Hwang presented at TEDMED The Hive, discussing the future of real-time, personalized health monitoring using tissue-integrated biosensors.
Dr. William Frist, a leading healthcare authority and public health advocate, joined Profusa’s board of directors to advise on the development of tissue-integrated sensors for real-time monitoring of body chemistry.
Live demonstration of Profusa’s sensor technology at CES 2016, showing real-time blood chemistry data collection.
Profusa introduced its injectable Lumee™ biosensor technology for continuous body chemistry tracking at the Pioneers Festival in Vienna, Austria.